<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39308871</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Effect of pioglitazone on inflammatory response and clinical outcome in T2DM patients with COVID-19: a randomized multicenter double-blind clinical trial.</ArticleTitle><Pagination><StartPage>1369918</StartPage><MedlinePgn>1369918</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1369918</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1369918</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Coronavirus disease 2019 (COVID-19) caused by the coronavirus SARS-CoV-2, has emerged as a rapidly spreading contagious disease across the globe. Recent studies showed that people with diabetes mellitus, severe obesity, and cardiovascular disease are at higher risk of mortality from COVID-19. It has been suggested that the increased risk is due to the chronic inflammatory state associated with type 2 diabetes. This study aimed to evaluate the efficacy of pioglitazone, a strong insulin sensitizer with anti-inflammatory properties, in improving the clinical outcomes of patients with type 2 diabetes admitted with moderate-severe COVID-19.</AbstractText><AbstractText Label="METHOD" NlmCategory="UNASSIGNED">We enrolled 350 patients with type 2 diabetes who were admitted to hospitals in Qatar and Kuwait with COVID-19. Patients were randomized to receive, in a double-blind fashion, pioglitazone (<i>n</i> = 189) or a matching placebo (<i>n</i> = 161) for 28 days. The study had two primary outcomes: (1) the incidence of a composite outcome composed of (a) the requirement for mechanical ventilation, (b) death, and (c) myocardial damage; and (2) an increase in C-reactive protein (CRP) levels.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The first primary outcome occurred in 28 participants (8%), and the secondary outcome occurred in 17. Treatment with pioglitazone showed a significant reduction in interleukin (IL)-3 levels compared with placebo treatment (mean (SD) 2.73 (± 2.14) [95% CI: 0.02, 1.1], <i>p</i> = 0.043 vs. 2.28 (± 1.67) [95% CI: - 0.23, 0.86], <i>p</i> = 0.3, respectively), with no effect seen in the levels of other inflammatory markers. Even though not significant, a few of the patients on pioglitazone exhibited serum troponin levels &gt; 3 times higher than the normal range seen in patients on placebo. On the other hand, more patients on pioglitazone were admitted to the ICU than those with placebo, and no significant difference in the CRP reduction was observed between the two groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The results of the present study demonstrate that pioglitazone treatment did not independently provide any additional clinical benefit to patients with type 2 diabetes admitted with a COVID-19 infection.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION" NlmCategory="UNASSIGNED">https://clinicaltrials.gov, identifier NCT04604223.</AbstractText><CopyrightInformation>Copyright © 2024 Baagar, Alessa, Abu-Farha, Abubaker, Alhumaidi, Franco Ceruto, Hamad, Omrani, Abdelrahman, Zaka-Ul Haq, Safi, Alhariri, Barman, Abdelmajid, Cancio, Elmekaty, Al-Khairi, Cherian, Jayyousi, Ahmed, Qaddoumi, Hajji, Esmaeel, Al-Andaleeb, Channanath, Devarajan, Ali, Thanaraj, Al-Sabah, Al-Mulla, Abdul-Ghani and Jayyousi.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Baagar</LastName><ForeName>Khaled</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Medicine Department, Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Alessa</LastName><ForeName>Thamer</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Jaber AlAhmed Hospital, Ministry of Health, Kuwait City, Kuwait.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Abu-Farha</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Translational Research, Dasman Diabetes Institute, Kuwait City, Kuwait.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abubaker</LastName><ForeName>Jehad</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Dasman Diabetes Institute, Kuwait City, Kuwait.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alhumaidi</LastName><ForeName>Heba</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Jaber AlAhmed Hospital, Ministry of Health, Kuwait City, Kuwait.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franco Ceruto</LastName><ForeName>Jose Antonio</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Medicine Department, Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamad</LastName><ForeName>Mohammad Khair</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Medicine Department, Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omrani</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medicine Department, Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdelrahman</LastName><ForeName>Salma</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medicine Department, Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaka-Ul Haq</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medicine Department, Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Safi</LastName><ForeName>Abdul Wajid</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Medicine Department, Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alhariri</LastName><ForeName>Bassem</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Medicine Department, Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barman</LastName><ForeName>Manish</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medicine Department, Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdelmajid</LastName><ForeName>Alaaeldin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medicine Department, Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cancio</LastName><ForeName>Humberto Vidal Denis</ForeName><Initials>HVD</Initials><AffiliationInfo><Affiliation>Medicine Department, Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elmekaty</LastName><ForeName>Eman</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Khairi</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Dasman Diabetes Institute, Kuwait City, Kuwait.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cherian</LastName><ForeName>Preethi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Dasman Diabetes Institute, Kuwait City, Kuwait.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jayyousi</LastName><ForeName>Lina</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Royal College of Surgeons in Ireland, Medical University of Bahrain, Manama, Bahrain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Translational Research, Dasman Diabetes Institute, Kuwait City, Kuwait.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qaddoumi</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pharmacology and Therapeutics Department, Faculty of Pharmacy, Kuwait University, Kuwait City, Kuwait.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hajji</LastName><ForeName>Sulaiman</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Jaber AlAhmed Hospital, Ministry of Health, Kuwait City, Kuwait.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esmaeel</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Jaber AlAhmed Hospital, Ministry of Health, Kuwait City, Kuwait.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Andaleeb</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Jaber AlAhmed Hospital, Ministry of Health, Kuwait City, Kuwait.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Channanath</LastName><ForeName>Arshad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dasman Diabetes Institute, Kuwait City, Kuwait.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devarajan</LastName><ForeName>Sriraman</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dasman Diabetes Institute, Kuwait City, Kuwait.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Hamad</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Dasman Diabetes Institute, Kuwait City, Kuwait.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thanaraj</LastName><ForeName>Thangavel Alphonse</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Dasman Diabetes Institute, Kuwait City, Kuwait.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Sabah</LastName><ForeName>Salman</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Jaber AlAhmed Hospital, Ministry of Health, Kuwait City, Kuwait.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Mulla</LastName><ForeName>Fahd</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Translational Research, Dasman Diabetes Institute, Kuwait City, Kuwait.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdul-Ghani</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Translational Research, Dasman Diabetes Institute, Kuwait City, Kuwait.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Diabetes, University of Texas Health Science Center, San Antonio, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jayyousi</LastName><ForeName>Amin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medicine Department, Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04604223</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>X4OV71U42S</RegistryNumber><NameOfSubstance UI="D000077205">Pioglitazone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077205" MajorTopicYN="Y">Pioglitazone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011780" MajorTopicYN="N" Type="Geographic">Qatar</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007730" MajorTopicYN="N" Type="Geographic">Kuwait</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">pioglitazone</Keyword><Keyword MajorTopicYN="N">type 2 diabetes</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>11</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>5</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39308871</ArticleId><ArticleId IdType="pmc">PMC11412854</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1369918</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-coV-2 spike glycoprotein. Cell. (2020). 181:281–92. doi: 10.1101/2020.02.19.956581</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.02.19.956581</ArticleId><ArticleId IdType="pmc">PMC7102599</ArticleId><ArticleId IdType="pubmed">32155444</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Chu H, Chan JF, Yuen KY. Middle East respiratory syndrome coronavirus infection: virus-host cell interactions and implications on pathogenesis. Virol J. (2015) 12:218. doi: 10.1186/s12985-015-0446-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-015-0446-6</ArticleId><ArticleId IdType="pmc">PMC4687146</ArticleId><ArticleId IdType="pubmed">26690369</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev. (2015) 28:465–522. doi: 10.1128/CMR.00102-14</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00102-14</ArticleId><ArticleId IdType="pmc">PMC4402954</ArticleId><ArticleId IdType="pubmed">25810418</ArticleId></ArticleIdList></Reference><Reference><Citation>Muniyappa R, Gubbi S. COVID-19 pandemic, corona viruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. (2020) 318:E736–41. doi: 10.1152/ajpendo.00124.2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00124.2020</ArticleId><ArticleId IdType="pmc">PMC7191633</ArticleId><ArticleId IdType="pubmed">32228322</ArticleId></ArticleIdList></Reference><Reference><Citation>Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. (2020) 323:1775–6. doi: 10.1001/jama.2020.4683</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.4683</ArticleId><ArticleId IdType="pubmed">32203977</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. (2020) 395:1054–62. doi: 10.1016/S0140-6736(20)30566-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. . Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. (2020) 180:934–43. doi: 10.1001/jamainternmed.2020.0994</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.0994</ArticleId><ArticleId IdType="pmc">PMC7070509</ArticleId><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. . Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. (2020) 382:1708–20. doi: 10.1056/NEJMoa2002032</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen CJ, Murphy KE, Fernandez ML. Impact of obesity and metabolic syndrome on immunity. Adv Nutr. (2016) 7:66–75. doi: 10.3945/an.115.010207</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/an.115.010207</ArticleId><ArticleId IdType="pmc">PMC4717890</ArticleId><ArticleId IdType="pubmed">26773015</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. (2011) 11:85–97. doi: 10.1038/nri2921</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2921</ArticleId><ArticleId IdType="pmc">PMC3518031</ArticleId><ArticleId IdType="pubmed">21252989</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard C, Wadowski M, Goruk S, Cameron L, Sharma AM, Field CJ. Individuals with obesity and type 2 diabetes have additional immune dysfunction compared with obese individuals who are metabolically healthy. BMJ Open Diabetes Res Care. (2017) 5:e000379. doi: 10.1136/bmjdrc-2016-000379</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjdrc-2016-000379</ArticleId><ArticleId IdType="pmc">PMC5530252</ArticleId><ArticleId IdType="pubmed">28761653</ArticleId></ArticleIdList></Reference><Reference><Citation>Luzi L, Radaelli MG. Influenza and obesity: its odd relationship and the lessons for COVID-19 pandemic. Acta Diabetol. (2020) 57(6):759–764. doi: 10.1007/s00592-020-01522-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00592-020-01522-8</ArticleId><ArticleId IdType="pmc">PMC7130453</ArticleId><ArticleId IdType="pubmed">32249357</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlsson EA, Hertz T, Johnson C, Mehle A, Krammer F, Schultz-Cherry S. Obesity outweighs protection conferred by adjuvanted influenza vaccination. mBio. (2016) 7. doi: 10.1128/mBio.01144-16</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01144-16</ArticleId><ArticleId IdType="pmc">PMC4981723</ArticleId><ArticleId IdType="pubmed">27486196</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. (2020) 323:1239–42. doi: 10.1001/jama.2020.2648</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu HJ, Wang LJ, Huang K, Guo QF, Lin BY, Liu YY, et al. . PPAR-gamma agonist pioglitazone alleviates inflammatory response induced by lipopolysaccharides in osteoblast cells. J Orthop Res. (2022) 40:2471–9. doi: 10.1002/jor.25279</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jor.25279</ArticleId><ArticleId IdType="pubmed">35072290</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan J, Nowell M, Chima R, Zingarelli B. Pioglitazone reduces inflammation through inhibition of NF-kappaB in polymicrobial sepsis. Innate Immun. (2014) 20:519–28. doi: 10.1177/1753425913501565</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1753425913501565</ArticleId><ArticleId IdType="pmc">PMC3954463</ArticleId><ArticleId IdType="pubmed">24029145</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez AD, Sathyanarayana P, Konduru S, Ye Y, Birnbaum Y, Bajaj M. The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes. Atherosclerosis. (2012) 223:204–8. doi: 10.1016/j.atherosclerosis.2012.04.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2012.04.016</ArticleId><ArticleId IdType="pubmed">22687642</ArticleId></ArticleIdList></Reference><Reference><Citation>Kipourou DK, Leyrat C, Alsheridah N, Almazeedi S, Al-Youha S, Jamal MH, et al. . Probabilities of ICU admission and hospital discharge according to patient characteristics in the designated COVID-19 hospital of Kuwait. BMC Public Health. (2021) 21:799. doi: 10.1186/s12889-021-10759-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-021-10759-z</ArticleId><ArticleId IdType="pmc">PMC8072736</ArticleId><ArticleId IdType="pubmed">33902520</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyland JE, Raja-Khan NT, Bettermann K, Haouzi PA, Leslie DL, Kraschnewski JL, et al. . Diabetes, drug treatment, and mortality in COVID-19: A multinational retrospective cohort study. Diabetes. (2021) 70:2903–16. doi: 10.2337/db21-0385</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db21-0385</ArticleId><ArticleId IdType="pmc">PMC8660979</ArticleId><ArticleId IdType="pubmed">34580086</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasankhani A, Bahrami A, Tavakoli-Far B, Iranshahi S, Ghaemi F, Akbarizadeh MR, et al. . The role of peroxisome proliferator-activated receptors in the modulation of hyperinflammation induced by SARS-CoV-2 infection: A perspective for COVID-19 therapy. Front Immunol. (2023) 14:1127358. doi: 10.3389/fimmu.2023.1127358</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1127358</ArticleId><ArticleId IdType="pmc">PMC9981974</ArticleId><ArticleId IdType="pubmed">36875108</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang WY, Schwartz EA, Permana PA, Reaven PD. Pioglitazone inhibits the expression of inflammatory cytokines from both monocytes and lymphocytes in patients with impaired glucose tolerance. Arterioscler Thromb Vasc Biol. (2008) 28:2312–8. doi: 10.1161/ATVBAHA.108.175687</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.108.175687</ArticleId><ArticleId IdType="pubmed">18818415</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrasekharan JA, Sharma-Walia N. Lipoxins: nature’s way to resolve inflammation. J Inflammation Res. (2015) 8:181–92. doi: 10.2147/JIR.S90380</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S90380</ArticleId><ArticleId IdType="pmc">PMC4598198</ArticleId><ArticleId IdType="pubmed">26457057</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker J, Dichter E, Lacorte G, Kerner D, Spur B, Rodriguez A, et al. . Lipoxin a4 increases survival by decreasing systemic inflammation and bacterial load in sepsis. Shock. (2011) 36:410–6. doi: 10.1097/SHK.0b013e31822798c1</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e31822798c1</ArticleId><ArticleId IdType="pubmed">21701419</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Wang X, Duan X, Poorun D, Xu J, Zhang S, et al. . Lipoxin A4 and its analog suppress inflammation by modulating HMGB1 translocation and expression in psoriasis. Sci Rep. (2017) 7:7100. doi: 10.1038/s41598-017-07485-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-07485-1</ArticleId><ArticleId IdType="pmc">PMC5541073</ArticleId><ArticleId IdType="pubmed">28769106</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu B, Walker JA, Temmermand D, Mian K, Spur B, Rodriguez A, et al. . Lipoxin A(4) promotes more complete inflammation resolution in sepsis compared to stable lipoxin A(4) analog. Prostaglandins Leukot Essent Fatty Acids. (2013) 89:47–53. doi: 10.1016/j.plefa.2013.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plefa.2013.04.005</ArticleId><ArticleId IdType="pubmed">23688707</ArticleId></ArticleIdList></Reference><Reference><Citation>Kung YA, Chiang HJ, Li ML, Gong YN, Chiu HP, Hung CT, et al. . Acyl-coenzyme A synthetase long-chain family member 4 is involved in viral replication organelle formation and facilitates virus replication via ferroptosis. mBio. (2022) 13:e0271721. doi: 10.1128/mbio.02717-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.02717-21</ArticleId><ArticleId IdType="pmc">PMC8764547</ArticleId><ArticleId IdType="pubmed">35038927</ArticleId></ArticleIdList></Reference><Reference><Citation>Setz C, Grosse M, Auth J, Froba M, Rauch P, Bausch A, et al. . Synergistic antiviral activity of pamapimod and pioglitazone against SARS-coV-2 and its variants of concern. Int J Mol Sci 23. (2022) 23. doi: 10.3390/ijms23126830</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23126830</ArticleId><ArticleId IdType="pmc">PMC9224751</ArticleId><ArticleId IdType="pubmed">35743273</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Wu Z, Jin Q, Liu J, Xu P. Identification and analysis of biomarkers associated with lipophagy and therapeutic agents for COVID-19. Viruses 16. (2024) 16. doi: 10.3390/v16060923</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v16060923</ArticleId><ArticleId IdType="pmc">PMC11209609</ArticleId><ArticleId IdType="pubmed">38932215</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>